Spyre Therapeutics (SYRE) CEO sells 15,000 shares in Rule 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Spyre Therapeutics, Inc.'s Chief Executive Officer, Cameron Turtle, reported selling a total of 15,000 shares of common stock in open-market transactions on March 2, 2026. The sales, executed under a Rule 10b5-1 trading plan adopted on June 20, 2025, were completed in two trades at weighted average prices of $41.73 and $42.49, each reflecting multiple executions within stated price ranges. Following these transactions, the CEO directly holds 642,540 shares of common stock, which includes 130,683 shares scheduled to vest in monthly installments through November 2026, subject to continued service.

Insider Trade Summary

Net Seller: 15,000 shares ($632,866)

Net Sell 2 txns

Insider Turtle Cameron

Role Chief Executive Officer

Sold 15,000 shs ($633K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,900	$41.73	$246K
Sale	Common Stock	9,100	$42.49	$387K

Holdings After Transaction: Common Stock — 651,640 shares (Direct)

Footnotes (1)

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.23 to $42.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Includes 130,683 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.23 to $42.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 09:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Turtle Cameron

(Last)

(First)

(Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM

02453

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/02/2026		S⁽¹⁾		5,900	D	$41.73⁽²⁾	651,640⁽³⁾	D
Common Stock	03/02/2026		S⁽¹⁾		9,100	D	$42.49⁽⁴⁾	642,540⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.23 to $42.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. Includes 130,683 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.23 to $42.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many Spyre Therapeutics (SYRE) shares did the CEO sell in this Form 4?

The CEO sold 15,000 shares of Spyre Therapeutics common stock. The sales occurred in two open-market transactions totaling 5,900 shares at $41.73 and 9,100 shares at $42.49, each representing weighted average prices across multiple executions within disclosed price ranges.

On what date did the Spyre Therapeutics (SYRE) CEO complete these stock sales?

Both reported stock sales took place on March 2, 2026. The Form 4 shows two separate open-market transactions in Spyre Therapeutics common stock on that date, each coded as an “S” transaction and described as a sale in open market or private transaction.

Were the Spyre Therapeutics (SYRE) CEO’s stock sales made under a Rule 10b5-1 plan?

Yes, the sales were executed under a Rule 10b5-1 trading plan. A footnote states the plan was adopted on June 20, 2025, indicating the transactions followed a pre-established trading schedule rather than being initiated at the CEO’s sole discretion at the time of sale.

What prices did the Spyre Therapeutics (SYRE) CEO receive for the shares sold?

The reported prices are weighted averages of $41.73 and $42.49 per share. Footnotes explain that the shares were sold in multiple transactions, with prices ranging from $41.23 to $42.19 and from $42.23 to $42.93, and detailed trade data is available on request.

How many Spyre Therapeutics (SYRE) shares does the CEO own after these transactions?

After the reported sales, the CEO directly owns 642,540 shares. This total includes 130,683 shares of common stock that vest in monthly installments through November 2026, contingent on the CEO’s continued service with the company on each vesting date.

What type of insider transaction is reported for Spyre Therapeutics (SYRE) in this Form 4?

The filing reports open-market sales of common stock by the CEO. Each transaction is coded “S” for a sale in open market or private transaction, reflecting non-derivative disposals of existing shares rather than option exercises, grants, or other derivative-related activity.